Janux Therapeutics (JANX)
Janux Therapeutics on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
5.3M
Short interest
settlement 2026-10-15
6.2
Days to cover
+0.3 days vs prior
67.2%
Short share of volume
2026-11-02
18,477
Fails to deliver
settlement 2026-09-01
Thu 5 Nov
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in JANX is 5,327,163 shares, down 564,802 shares over the last month. Over the last 48 readings it ranged from 4,185,628 shares (15 November 2024) to 11,548,285 shares (15 May 2025). At the reported average volume of 860K shares a day that is 6.2 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/janx" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 5,327,163 | -6.3% | 859,874 | 6.20 |
| 2026-09-30 | 5,684,346 | -3.5% | 969,533 | 5.86 |
| 2026-09-15 | 5,891,965 | -2.8% | 999,885 | 5.89 |
| 2026-08-31 | 6,063,535 | -8.5% | 776,426 | 7.81 |
| 2026-08-14 | 6,626,696 | +11.9% | 607,942 | 10.90 |
| 2026-07-31 | 5,922,899 | -8.2% | 765,256 | 7.74 |
| 2026-07-15 | 6,454,019 | -9.2% | 1,003,518 | 6.43 |
| 2026-06-30 | 7,108,085 | -6.7% | 1,978,810 | 3.59 |
| 2026-06-15 | 7,615,380 | -5.9% | 694,792 | 10.96 |
| 2026-05-29 | 8,091,847 | +3.4% | 1,184,704 | 6.83 |
| 2026-05-15 | 7,827,096 | -1.3% | 810,461 | 9.66 |
| 2026-04-30 | 7,932,981 | +6.6% | 1,072,535 | 7.40 |
| 2026-04-15 | 7,440,069 | -3.9% | 900,076 | 8.27 |
| 2026-03-31 | 7,744,629 | -22.7% | 1,405,554 | 5.51 |
| 2026-03-13 | 10,020,131 | +0.2% | 833,971 | 12.01 |
| 2026-02-27 | 9,996,191 | -1.5% | 798,369 | 12.52 |
| 2026-02-13 | 10,144,569 | -3.2% | 1,375,257 | 7.38 |
| 2026-01-30 | 10,476,584 | +10.9% | 1,877,069 | 5.58 |
| 2026-01-15 | 9,444,405 | +2.2% | 1,483,872 | 6.36 |
| 2025-12-31 | 9,239,650 | +24.9% | 2,641,124 | 3.50 |
| 2025-12-15 | 7,395,136 | -2.8% | 3,732,771 | 1.98 |
| 2025-11-28 | 7,606,181 | +6.7% | 1,100,209 | 6.91 |
| 2025-11-14 | 7,131,951 | +2.7% | 1,042,069 | 6.84 |
| 2025-10-31 | 6,946,508 | -18.9% | 1,197,554 | 5.80 |
| 2025-10-15 | 8,562,496 | -4.1% | 1,042,241 | 8.22 |
| 2025-09-30 | 8,932,119 | +7.6% | 820,902 | 10.88 |
| 2025-09-15 | 8,301,729 | +3.1% | 644,393 | 12.88 |
| 2025-08-29 | 8,048,523 | -0.3% | 628,118 | 12.81 |
| 2025-08-15 | 8,075,479 | -7.5% | 937,816 | 8.61 |
| 2025-07-31 | 8,733,357 | -9.5% | 840,950 | 10.39 |
| 2025-07-15 | 9,654,389 | -5.9% | 777,953 | 12.41 |
| 2025-06-30 | 10,261,166 | -3.3% | 743,206 | 13.81 |
| 2025-06-13 | 10,610,234 | -0.6% | 595,927 | 17.80 |
| 2025-05-30 | 10,671,942 | -7.6% | 1,130,628 | 9.44 |
| 2025-05-15 | 11,548,285 | +19.6% | 1,396,485 | 8.27 |
| 2025-04-30 | 9,651,866 | +3.3% | 578,776 | 16.68 |
| 2025-04-15 | 9,340,605 | -7.5% | 1,284,757 | 7.27 |
| 2025-03-31 | 10,099,102 | -3.8% | 705,789 | 14.31 |
| 2025-03-14 | 10,497,950 | +12.0% | 957,362 | 10.97 |
| 2025-02-28 | 9,371,657 | +3.1% | 819,741 | 11.43 |
| 2025-02-14 | 9,091,177 | +11.8% | 970,126 | 9.37 |
| 2025-01-31 | 8,131,557 | -4.9% | 963,476 | 8.44 |
| 2025-01-15 | 8,552,992 | +11.4% | 1,303,092 | 6.56 |
| 2024-12-31 | 7,678,286 | +19.7% | 750,200 | 10.23 |
| 2024-12-13 | 6,414,759 | +43.3% | 2,483,916 | 2.58 |
| 2024-11-29 | 4,477,253 | +7.0% | 657,605 | 6.81 |
| 2024-11-15 | 4,185,628 | -2.9% | 666,999 | 6.28 |
| 2024-10-31 | 4,310,503 | -0.5% | 686,577 | 6.28 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of JANX volume is 67.2%, up 10.1 points over the last five sessions. Over the last 30 readings it ranged from 17.4% (29 October 2026) to 79.7% (20 October 2026). The latest reading is 11.0 points above the 30-session average of 56.2%, on 136K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 91K | 136K | 67.2% | 200 |
| 2026-10-30 | 68K | 159K | 43.0% | 0 |
| 2026-10-29 | 87K | 500K | 17.4% | 40 |
| 2026-10-28 | 108K | 365K | 29.4% | 0 |
| 2026-10-27 | 93K | 221K | 42.1% | 0 |
| 2026-10-26 | 68K | 120K | 57.1% | 0 |
| 2026-10-23 | 66K | 119K | 55.8% | 0 |
| 2026-10-22 | 58K | 116K | 49.7% | 0 |
| 2026-10-21 | 86K | 202K | 42.6% | 0 |
| 2026-10-20 | 251K | 314K | 79.7% | 508 |
| 2026-10-19 | 204K | 279K | 73.0% | 0 |
| 2026-10-16 | 122K | 197K | 61.9% | 189 |
| 2026-10-15 | 92K | 175K | 52.4% | 0 |
| 2026-10-14 | 88K | 199K | 44.0% | 0 |
| 2026-10-13 | 184K | 287K | 64.1% | 68 |
| 2026-10-12 | 140K | 237K | 59.0% | 0 |
| 2026-10-09 | 200K | 568K | 35.3% | 73 |
| 2026-10-08 | 314K | 560K | 56.1% | 120 |
| 2026-10-07 | 218K | 450K | 48.4% | 0 |
| 2026-10-06 | 230K | 324K | 71.0% | 0 |
| 2026-10-05 | 127K | 197K | 64.5% | 1,000 |
| 2026-10-02 | 233K | 321K | 72.6% | 0 |
| 2026-10-01 | 165K | 256K | 64.6% | 8 |
| 2026-09-30 | 149K | 231K | 64.7% | 10 |
| 2026-09-29 | 110K | 162K | 67.6% | 0 |
| 2026-09-28 | 99K | 155K | 63.8% | 0 |
| 2026-09-25 | 132K | 282K | 46.9% | 0 |
| 2026-09-24 | 239K | 492K | 48.6% | 0 |
| 2026-09-23 | 298K | 398K | 74.9% | 0 |
| 2026-09-22 | 130K | 192K | 67.5% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 1 September 2026, the fails-to-deliver balance in JANX is 18,477 shares, up 15,489 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (8 July 2026) to 151,493 shares (26 November 2025).
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-01 | 18,477 | $18.22 | $337K |
| 2026-08-24 | 2,988 | $17.39 | $52K |
| 2026-08-21 | 1,453 | $17.28 | $25K |
| 2026-07-23 | 3,011 | $15.62 | $47K |
| 2026-07-22 | 715 | $16.26 | $12K |
| 2026-07-08 | 1 | $16.15 | $16 |
| 2026-07-02 | 483 | $14.66 | $7K |
| 2026-06-30 | 17,235 | $15.33 | $264K |
| 2026-06-08 | 55 | $13.36 | $735 |
| 2026-05-14 | 685 | $14.61 | $10K |
| 2026-04-20 | 16,123 | $15.82 | $255K |
| 2026-03-16 | 95 | $13.58 | $1K |
| 2026-03-09 | 1,047 | $13.84 | $14K |
| 2026-03-06 | 505 | $13.97 | $7K |
| 2026-03-05 | 250 | $14.35 | $4K |
| 2026-03-04 | 5 | $13.44 | $67 |
| 2026-02-27 | 422 | $13.80 | $6K |
| 2026-02-20 | 22,163 | $13.42 | $297K |
| 2025-12-30 | 56 | $14.07 | $788 |
| 2025-12-03 | 4,306 | $15.86 | $68K |
| 2025-12-02 | 199 | $33.99 | $7K |
| 2025-12-01 | 99 | $34.09 | $3K |
| 2025-11-26 | 151,493 | $34.74 | $5.3M |
| 2025-11-24 | 276 | $28.80 | $8K |
| 2025-11-06 | 2,649 | $27.54 | $73K |
| 2025-11-04 | 2,116 | $27.37 | $58K |
| 2025-10-17 | 532 | $27.20 | $14K |
| 2025-10-16 | 1,118 | $28.28 | $32K |
| 2025-10-14 | 1,563 | $26.29 | $41K |
| 2025-10-09 | 113 | $24.20 | $3K |
Insider trades
SEC Form 4, newest first. JSONNo open-market insider trades were reported for JANX in the last 90 days. The most recent filings are listed below. Latest filing: Campbell David Alan (President and CEO) on 2026-07-31.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-07-31 | Campbell David Alan | President and CEO | Gift | 124K | $0.00 | $0 | 265K |
| 2026-07-08 | Campbell David Alan | President and CEO | Exercise or conversion | 7K | $4.21 | $29K | 389K |
| 2026-06-11 | Barrett Ronald W | Director | Grant | 6K | $0.00 | $0 | 12K |
| 2026-06-11 | CAPPS VICKIE L | Director | Grant | 6K | $0.00 | $0 | 80K |
| 2026-06-11 | DOBMEIER ERIC | Director | Grant | 6K | $0.00 | $0 | 15K |
| 2026-06-11 | Hernday Natasha | Director | Grant | 6K | $0.00 | $0 | 15K |
| 2026-06-11 | Kung Winston | Director | Grant | 6K | $0.00 | $0 | 12K |
| 2026-06-11 | Simson Jake | Director | Grant | 6K | $0.00 | $0 | 12K |
| 2026-06-11 | RA Capital Nexus Fund II, L.P. | Director | Grant | 6K | $0.00 | $0 | 12K |
| 2026-06-02 | Doyle Janeen Noel | Chief Corp. & Bus. Dev. Ofcr | Sell | 4K | $14.03 | $57K | 76K |
| 2026-05-11 | Dobek Maria | Vice President, Accounting | Sell | 2K | $14.17 | $29K | 32K |
| 2026-02-02 | Go William | Chief Medical Officer | Grant | 44K | $0.00 | $0 | 44K |
| 2026-01-02 | McIver Zachariah | Chief Medical Officer | Grant | 29K | $0.00 | $0 | 52K |
| 2026-01-02 | McIver Zachariah | Chief Medical Officer | Sell | 3K | $13.73 | $37K | 23K |
| 2026-01-02 | Winter Charles M. | Chief Technical Officer | Grant | 29K | $0.00 | $0 | 106K |
| 2026-01-02 | Winter Charles M. | Chief Technical Officer | Sell | 2K | $13.73 | $33K | 78K |
| 2026-01-02 | Meyer Andrew Hollman | Chief Business Officer | Sell | 2K | $13.73 | $26K | 83K |
| 2026-01-02 | Doyle Janeen Noel | Chief Corp. & Bus. Dev. Ofcr | Grant | 36K | $0.00 | $0 | 80K |
| 2026-01-02 | Dobek Maria | Vice President, Accounting | Grant | 19K | $0.00 | $0 | 34K |
| 2026-01-02 | Dobek Maria | Vice President, Accounting | Sell | 1K | $13.73 | $20K | 15K |
| 2026-01-02 | DiRaimondo Thomas | Chief Scientific Officer | Grant | 31K | $0.00 | $0 | 156K |
| 2026-01-02 | DiRaimondo Thomas | Chief Scientific Officer | Sell | 3K | $13.73 | $34K | 124K |
| 2026-01-02 | Campbell David Alan | President and CEO | Grant | 97K | $0.00 | $0 | 382K |
| 2026-01-02 | Campbell David Alan | President and CEO | Sell | 8K | $13.73 | $111K | 285K |
| 2025-12-01 | Meyer Andrew Hollman | Chief Business Officer | Sell | 633 | $33.52 | $21K | 85K |
| 2025-12-01 | Meyer Andrew Hollman | Chief Business Officer | Sell | 3K | $32.85 | $89K | 86K |
| 2025-12-01 | Meyer Andrew Hollman | Chief Business Officer | Exercise or conversion | 3K | $10.59 | $35K | 88K |
| 2025-11-14 | Meyer Andrew Hollman | Chief Business Officer | Sell | 3K | $30.00 | $100K | 85K |
| 2025-11-14 | Meyer Andrew Hollman | Chief Business Officer | Exercise or conversion | 3K | $10.59 | $35K | 88K |
| 2025-10-28 | Meyer Andrew Hollman | Chief Business Officer | Sell | 17K | $30.06 | $501K | 82K |
| 2025-10-28 | Meyer Andrew Hollman | Chief Business Officer | Exercise or conversion | 7K | $10.59 | $71K | 99K |
| 2025-10-28 | Meyer Andrew Hollman | Chief Business Officer | Exercise or conversion | 10K | $4.21 | $42K | 92K |
| 2025-06-11 | RA Capital Healthcare Fund LP | Director,TenPercentOwner | Grant | 4K | $0.00 | $0 | 6K |
| 2025-06-11 | RA CAPITAL MANAGEMENT, L.P. | Director, 10% owner | Grant | 4K | $0.00 | $0 | 6K |
| 2025-06-11 | McNulty Alana B. | Director | Grant | 4K | $0.00 | $0 | 6K |
| 2025-06-11 | Simson Jake | Director | Grant | 4K | $0.00 | $0 | 6K |
| 2025-06-11 | Kung Winston | Director | Grant | 4K | $0.00 | $0 | 6K |
| 2025-06-11 | Hernday Natasha | Director | Grant | 4K | $0.00 | $0 | 9K |
| 2025-06-11 | Gujrathi Sheila | Director | Grant | 4K | $0.00 | $0 | 119K |
| 2025-06-11 | DOBMEIER ERIC | Director | Grant | 4K | $0.00 | $0 | 10K |
| 2025-06-11 | CAPPS VICKIE L | Director | Grant | 4K | $0.00 | $0 | 74K |
| 2025-06-11 | Barrett Ronald W | Director | Grant | 4K | $0.00 | $0 | 6K |
| 2025-06-02 | Doyle Janeen Noel | Chief Corp. & Bus. Dev. Ofcr | Grant | 44K | $0.00 | $0 | 44K |
| 2025-05-01 | Meyer Andrew Hollman | Chief Business Officer | Exercise or conversion | 3K | $4.21 | $14K | 85K |
| 2025-05-01 | Meyer Andrew Hollman | Chief Business Officer | Sell | 3K | $31.95 | $94K | 83K |
| 2025-05-01 | Meyer Andrew Hollman | Chief Business Officer | Sell | 400 | $32.60 | $13K | 82K |
| 2025-04-21 | Meyer Andrew Hollman | Chief Business Officer | Exercise or conversion | 3K | $4.21 | $14K | 85K |
| 2025-04-21 | Meyer Andrew Hollman | Chief Business Officer | Sell | 3K | $30.00 | $100K | 82K |
| 2025-03-07 | RA Capital Healthcare Fund LP | Director,TenPercentOwner | Buy | 110K | $31.02 | $3.4M | 10.1M |
| 2025-03-06 | RA Capital Healthcare Fund LP | Director,TenPercentOwner | Buy | 372K | $30.78 | $11.5M | 10.0M |
| 2025-03-05 | RA Capital Healthcare Fund LP | Director,TenPercentOwner | Buy | 37K | $31.30 | $1.2M | 9.7M |
| 2025-03-05 | RA Capital Healthcare Fund LP | Director,TenPercentOwner | Buy | 304K | $30.56 | $9.3M | 9.6M |
| 2025-03-03 | Meyer Andrew Hollman | Chief Business Officer | Sell | 2K | $31.88 | $78K | 83K |
| 2025-03-03 | Meyer Andrew Hollman | Chief Business Officer | Sell | 901 | $32.85 | $30K | 82K |
| 2025-03-03 | Meyer Andrew Hollman | Chief Business Officer | Exercise or conversion | 3K | $4.21 | $14K | 85K |
| 2025-02-03 | Meyer Andrew Hollman | Chief Business Officer | Exercise or conversion | 3K | $4.21 | $14K | 85K |
| 2025-02-03 | Meyer Andrew Hollman | Chief Business Officer | Sell | 2K | $42.08 | $102K | 83K |
| 2025-02-03 | Meyer Andrew Hollman | Chief Business Officer | Sell | 816 | $42.77 | $35K | 82K |
| 2025-02-03 | Meyer Andrew Hollman | Chief Business Officer | Sell | 100 | $43.60 | $4K | 82K |
| 2025-01-07 | Campbell David Alan | President and CEO | Sell | 5K | $60.00 | $300K | 293K |
| 2025-01-02 | Meyer Andrew Hollman | Chief Business Officer | Sell | 200 | $57.37 | $11K | 82K |
| 2025-01-02 | Meyer Andrew Hollman | Chief Business Officer | Sell | 3K | $55.76 | $192K | 83K |
| 2025-01-02 | Meyer Andrew Hollman | Chief Business Officer | Sell | 1K | $56.78 | $57K | 82K |
| 2025-01-02 | Meyer Andrew Hollman | Chief Business Officer | Grant | 18K | $0.00 | $0 | 95K |
| 2025-01-02 | Meyer Andrew Hollman | Chief Business Officer | Sell | 3K | $53.76 | $157K | 93K |
| 2025-01-02 | Meyer Andrew Hollman | Chief Business Officer | Sell | 6K | $54.51 | $314K | 87K |
| 2025-01-02 | Dobek Maria | Vice President, Accounting | Grant | 14K | $0.00 | $0 | 14K |
| 2025-01-02 | DiRaimondo Thomas | Chief Scientific Officer | Grant | 24K | $0.00 | $0 | 130K |
| 2025-01-02 | Robinson Byron | Chief Strategy Officer | Grant | 28K | $0.00 | $0 | 28K |
| 2025-01-02 | Campbell David Alan | President and CEO | Grant | 81K | $0.00 | $0 | 298K |
| 2025-01-02 | Winter Charles M. | Chief Technical Officer | Grant | 23K | $0.00 | $0 | 77K |
| 2025-01-02 | McIver Zachariah | Chief Medical Officer | Grant | 26K | $0.00 | $0 | 26K |
| 2024-12-24 | Campbell David Alan | President and CEO | Sell | 25K | $56.19 | $1.4M | 217K |
| 2024-12-19 | Meyer Andrew Hollman | Chief Business Officer | Exercise or conversion | 10K | $20.24 | $200K | 77K |
| 2024-12-19 | Meyer Andrew Hollman | Chief Business Officer | Exercise or conversion | 1 | $14.02 | $14 | 77K |
| 2024-12-03 | Campbell David Alan | President and CEO | Sell | 15K | $67.00 | $1.0M | 242K |
| 2024-11-25 | Campbell David Alan | President and CEO | Sell | 18K | $51.43 | $940K | 264K |
| 2024-11-25 | Campbell David Alan | President and CEO | Sell | 7K | $52.04 | $350K | 257K |
| 2024-11-05 | CAPPS VICKIE L | Director | Other transaction | 2K | $0.00 | $0 | 70K |
| 2024-11-05 | Gujrathi Sheila | Director | Other transaction | 5K | $0.00 | $0 | 115K |
| 2024-10-28 | Campbell David Alan | President and CEO | Sell | 11K | $53.94 | $599K | 282K |
| 2024-10-28 | Campbell David Alan | President and CEO | Sell | 14K | $53.22 | $740K | 293K |
| 2024-10-18 | Avalon BioVentures SPV I, L.P. | TenPercentOwner | Sell | 103K | $50.30 | $5.2M | 2.6M |
| 2024-10-18 | Avalon BioVentures SPV I, L.P. | TenPercentOwner | Sell | 20K | $50.30 | $1.0M | 509K |
| 2024-10-18 | Avalon BioVentures SPV I, L.P. | TenPercentOwner | Sell | 105K | $50.30 | $5.3M | 2.7M |
| 2024-10-18 | Avalon BioVentures SPV I, L.P. | TenPercentOwner | Sell | 15K | $51.18 | $791K | 2.6M |
| 2024-10-18 | Avalon BioVentures SPV I, L.P. | TenPercentOwner | Sell | 3K | $51.18 | $153K | 506K |
| 2024-10-18 | Avalon BioVentures SPV I, L.P. | TenPercentOwner | Sell | 16K | $51.18 | $808K | 2.7M |
| 2024-10-18 | Avalon BioVentures SPV I, L.P. | TenPercentOwner | Sell | 105K | $44.75 | $4.7M | 401K |
| 2024-10-18 | Avalon BioVentures SPV I, L.P. | TenPercentOwner | Sell | 553K | $44.75 | $24.8M | 2.1M |
| 2024-10-18 | Avalon BioVentures SPV I, L.P. | TenPercentOwner | Sell | 542K | $44.75 | $24.2M | 2.1M |
| 2024-10-18 | Kolchinsky Peter | Director,TenPercentOwner | Buy | 1.2M | $44.75 | $53.7M | 9.3M |
| 2024-10-17 | Avalon BioVentures SPV I, L.P. | TenPercentOwner | Sell | 2K | $50.02 | $92K | 6K |
| 2024-10-17 | Avalon BioVentures SPV I, L.P. | TenPercentOwner | Exercise or conversion | 237 | $39.80 | $9K | 8K |
| 2024-10-17 | Avalon BioVentures SPV I, L.P. | TenPercentOwner | Exercise or conversion | 836 | $17.00 | $14K | 7K |
| 2024-10-17 | Avalon BioVentures SPV I, L.P. | TenPercentOwner | Exercise or conversion | 348 | $13.22 | $5K | 8K |
| 2024-10-16 | Avalon BioVentures SPV I, L.P. | TenPercentOwner | Sell | 60K | $49.69 | $3.0M | 2.8M |
| 2024-10-16 | Avalon BioVentures SPV I, L.P. | TenPercentOwner | Sell | 12K | $49.69 | $579K | 535K |
| 2024-10-16 | Avalon BioVentures SPV I, L.P. | TenPercentOwner | Sell | 61K | $49.69 | $3.1M | 2.8M |
| 2024-10-16 | Avalon BioVentures SPV I, L.P. | TenPercentOwner | Sell | 29K | $50.61 | $1.5M | 2.7M |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON11 Form 144 notices on file for JANX worth $8.3M at the prices reported; 0 in the last 90 days worth $0. Latest: Janeen Noel Doyle filed on 2026-06-02 to sell 4,059 shares ($57K) from 2026-06-02.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-06-02 | Janeen Noel DoyleOfficer | 4K | $57K | 0.007% | 2026-06-02 | Morgan Stanley Smith Barney LLC |
| 2026-04-13 | ANDY MEYERFormer Affiliate | 2K | $28K | 0.003% | 2026-04-13 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-04-02 | ZACHARIAH A MCIVERFormer Officer | 75K | $1.1M | 0.123% | 2026-04-02 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-26 | ANDY MEYERFormer Affiliate | 179K | $2.6M | 0.297% | 2026-01-26 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-23 | ANDY MEYERFormer Affiliate | 118K | $1.7M | 0.196% | 2026-01-23 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-15 | BYRON C ROBINSONOfficer | 17K | $258K | 0.028% | 2025-12-15 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-08 | BYRON C ROBINSONOfficer | 50K | $826K | 0.083% | 2025-12-08 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-02 | BYRON C ROBINSONOfficer | 63K | $1.0M | 0.105% | 2025-12-02 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-01 | ANDREW MEYEROfficer | 3K | $114K | 0.006% | 2025-12-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-14 | ANDREW MEYEROfficer | 3K | $92K | 0.006% | 2025-11-14 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-10-28 | ANDREW MEYEROfficer | 17K | $456K | 0.028% | 2025-10-28 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON5 holders report 5% or more of JANX in their latest filing, all on Schedule 13G (passive). The largest reported stake is JANUS HENDERSON GROUP PLC at 6.9% of the class (4,196,409 shares), filed 2026-05-15 for an event on 2026-03-31.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-14 | 13G/Ano. 1 | Point72 Capital Advisors, Inc.corporation | 2.0M | 3.3% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Steven A. Cohenindividual | 2.0M | 3.3% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Point72 Asset Management, L.P.partnership | 2.0M | 3.3% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 6 | JANUS HENDERSON GROUP Ltd.parent holding company | 172K | 0.3% | 2026-06-30 |
| 2026-07-28 | 13G/Ano. 1 | BlackRock, Inc.parent holding company | 4.1M | 6.7% | 2026-06-30 |
| 2026-05-15 | 13G/Ano. 5 | JANUS HENDERSON GROUP PLCparent holding company | 4.2M | 6.9% | 2026-03-31 |
| 2026-05-12 | 13G | STATE STREET CORPORATIONparent holding company | 2.5M | 4.1% | 2026-03-31 |
| 2026-05-06 | 13G/Ano. 5 | Abigail P. Johnsonindividual | 2.5M | 4.2% | 2026-03-31 |
| 2026-05-06 | 13G/Ano. 5 | FMR LLCparent holding company | 2.5M | 4.2% | 2026-03-31 |
| 2026-02-06 | 13G | W. Lawrence Hawkinsparent holding company, individual | 3.2M | 5.3% | 2026-02-03 |
| 2026-02-06 | 13G | Prosight Partners, LLCother entity | 3.2M | 5.2% | 2026-02-03 |
| 2026-02-06 | 13G | Prosight Management, LPinvestment adviser | 3.2M | 5.2% | 2026-02-03 |
| 2026-02-06 | 13G | Prosight Plus Fund, LPpartnership | 685K | 1.1% | 2026-02-03 |
| 2026-02-06 | 13G | Prosight Fund, LPpartnership | 148K | 0.2% | 2026-02-03 |
13F holders
Tracked managers holding JANX at their latest 13F. JSON6 of the 30 tracked managers held JANX at their latest 13F, $93.9M in total at quarter-end prices. Point72 Asset Management is the largest at $30.6M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 6 added shares and 0 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Point72 Asset Management | 2026-06-30 | 2.0M | $30.6M | 0.03% | +838K |
| Two Sigma Investments | 2026-06-30 | 1.2M | $18.5M | 0.01% | +1.1M |
| Citadel Advisors | 2026-06-30 | 1.2M | $18.4M | 0.00% | +849K |
| D. E. Shaw & Co. | 2026-06-30 | 1.1M | $16.8M | 0.01% | +998K |
| Millennium Management | 2026-06-30 | 505K | $7.7M | 0.00% | +118K |
| AQR Capital Management | 2026-06-30 | 108K | $1.7M | 0.00% | new |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Janux Therapeutics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Janux Therapeutics (JANX), SEC CIK 1817713, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-01.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-06-02.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-14.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-06.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-07-31.JSON and CSV
- Company record
- EDGAR filing index for CIK 1817713Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of JANX is sold short?
5,327,163 shares were held short at the 2026-10-15 settlement, 6.2 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is JANX's daily short volume?
On 2026-11-02, 91,315 of the 135,929 JANX shares reported to FINRA were sold short, 67.2% of the day's reported volume. Short volume is a flow for one day, not a position.
Does JANX have fails to deliver?
The SEC's latest file shows 18,477 JANX shares failed to deliver at settlement 2026-09-01. Fails are reported per settlement date and published twice a month with a lag.
Are JANX insiders buying or selling?
No open-market insider trades were reported for JANX in the last 90 days. The most recent filings are listed below. Latest filing: Campbell David Alan (President and CEO) on 2026-07-31.
Have JANX insiders filed to sell?
11 Form 144 notices on file for JANX worth $8.3M at the prices reported; 0 in the last 90 days worth $0. Latest: Janeen Noel Doyle filed on 2026-06-02 to sell 4,059 shares ($57K) from 2026-06-02.
Who owns 5% or more of JANX?
5 holders report 5% or more of JANX in their latest filing, all on Schedule 13G (passive). The largest reported stake is JANUS HENDERSON GROUP PLC at 6.9% of the class (4,196,409 shares), filed 2026-05-15 for an event on 2026-03-31.
Which tracked 13F managers own JANX?
6 of the 30 tracked 13F managers held JANX shares at their latest filing, $93.9M in all. The largest: Steve Cohen's Point72 Asset Management (2.0M shares, $30.6M), Two Sigma Investments (1.2M shares, $18.5M), Ken Griffin's Citadel Advisors (1.2M shares, $18.4M), D. E. Shaw & Co. (1.1M shares, $16.8M), Izzy Englander's Millennium Management (505K shares, $7.7M), Cliff Asness's AQR Capital Management (108K shares, $1.7M).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.